Option Care Health (NASDAQ:OPCH) Issues Quarterly Earnings Results

Posted by George Bondi on Jul 31st, 2026

Option Care Health (NASDAQ:OPCH – Get Free Report) released its earnings results on Wednesday. The company reported $0.45 earnings per share for the quarter, beating analysts’ consensus estimates of $0.43 by $0.02, FiscalAI reports. The company had revenue of $1.44 billion for the quarter, compared to analysts’ expectations of $1.42 billion. Option Care Health had a net margin of 3.68% and a return on equity of 18.74%. Option Care Health’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.41 EPS. Option Care Health updated its FY 2026 guidance to 1.850-1.920 EPS.

Here are the key takeaways from Option Care Health’s conference call:

Second-quarter results exceeded expectations: Revenue rose 2% year over year to $1.4 billion, adjusted EBITDA increased 3% to $117.5 million, adjusted EPS grew to $0.45, and operating cash flow reached $184 million.
The acute therapy portfolio delivered another quarter of high-single-digit organic growth, while IG Neuro and rare-and-orphan therapies also posted sequential and year-over-year growth. The company added five ambulatory infusion facilities, with clinic visits up more than 20% year over year.
Management reported stabilization and sequential patient-census growth in its chronic inflammatory disease portfolio after the first-quarter reset, and expects further improvement through the remainder of 2026. Commercial-team realignment, technology deployment, and AI-enabled workflow improvements are intended to support additional revenue and productivity gains into 2027.
Option Care repurchased $150 million of stock during the quarter—nearly 5% of shares outstanding—while ending the period with a 2.1x net debt-to-leverage ratio and $525 million remaining under its authorization.
Full-year revenue guidance was maintained at $5.675 billion–$5.775 billion, while adjusted EBITDA guidance narrowed to $480 million–$495 million and adjusted EPS to $1.85–$1.92. Management continues to expect approximately 600 basis points of revenue pressure and a $55 million gross-profit headwind from the chronic inflammatory disease portfolio in 2026.

Option Care Health Trading Up 2.2%

OPCH traded up $0.48 on Friday, hitting $22.94. The company had a trading volume of 1,633,168 shares, compared to its average volume of 2,554,514. The company has a market cap of $3.60 billion, a PE ratio of 17.23, a PEG ratio of 1.33 and a beta of 0.65. Option Care Health has a 12-month low of $18.01 and a 12-month high of $36.80. The company has a quick ratio of 1.07, a current ratio of 1.47 and a debt-to-equity ratio of 0.91. The business’s fifty day simple moving average is $21.45 and its 200 day simple moving average is $26.82.

Analyst Upgrades and Downgrades

OPCH has been the topic of a number of recent analyst reports. Morgan Stanley set a $28.00 price target on Option Care Health in a report on Wednesday, May 6th. Bank of America cut Option Care Health from a “buy” rating to a “neutral” rating and set a $22.00 target price for the company. in a research report on Friday, May 1st. Zacks Research raised Option Care Health from a “strong sell” rating to a “hold” rating in a research note on Monday, July 6th. Stephens reissued an “equal weight” rating and issued a $24.00 price target (down from $30.00) on shares of Option Care Health in a report on Friday, July 17th. Finally, Truist Financial set a $30.00 price target on Option Care Health in a research note on Friday, May 1st. Seven investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Option Care Health has an average rating of “Hold” and an average target price of $29.92.

Get Our Latest Stock Report on OPCH

Insiders Place Their Bets

In related news, Director Harry M. Jansen Kraemer, Jr. bought 36,610 shares of the company’s stock in a transaction dated Monday, May 4th. The stock was purchased at an average price of $21.41 per share, for a total transaction of $783,820.10. Following the acquisition, the director owned 450,000 shares in the company, valued at $9,634,500. This trade represents a 8.86% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO John Charles Rademacher bought 12,500 shares of the business’s stock in a transaction dated Monday, May 4th. The shares were bought at an average cost of $21.18 per share, for a total transaction of $264,750.00. Following the transaction, the chief executive officer owned 695,152 shares in the company, valued at approximately $14,723,319.36. The trade was a 1.83% increase in their position. The SEC filing for this purchase provides additional information. Insiders have purchased 73,264 shares of company stock valued at $1,548,316 over the last ninety days. 1.70% of the stock is owned by insiders.

Institutional Trading of Option Care Health

A number of institutional investors have recently bought and sold shares of OPCH. Pacer Advisors Inc. increased its position in Option Care Health by 97.1% during the fourth quarter. Pacer Advisors Inc. now owns 42,121 shares of the company’s stock valued at $1,342,000 after acquiring an additional 20,751 shares during the last quarter. Invesco Ltd. lifted its holdings in shares of Option Care Health by 19.6% in the 4th quarter. Invesco Ltd. now owns 534,551 shares of the company’s stock worth $17,031,000 after acquiring an additional 87,721 shares during the last quarter. EP Wealth Advisors LLC bought a new stake in shares of Option Care Health in the 4th quarter worth about $225,000. Fuller & Thaler Asset Management Inc. boosted its stake in shares of Option Care Health by 12.1% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 6,958,800 shares of the company’s stock worth $221,707,000 after purchasing an additional 752,058 shares during the period. Finally, Freestone Grove Partners LP purchased a new position in shares of Option Care Health during the 4th quarter worth about $29,181,000. 98.05% of the stock is currently owned by institutional investors.

About Option Care Health

(Get Free Report)

Option Care Health (NASDAQ: OPCH) is a leading provider of home and alternate site infusion services in the United States. The company specializes in the administration of injectable therapies, including antibiotics, nutrition, hydration, immunoglobulin, pain management and specialty pharmaceuticals. Through its nationwide network of infusion pharmacies and nursing professionals, Option Care Health delivers customized care plans and in-home nursing visits to patients managing complex or chronic conditions outside of a hospital setting.

Option Care Health traces its current structure to the completion of its merger with BioScrip in early 2021, combining two of the industry’s most experienced home infusion businesses.